MedPath

Evaluation of the Efficacy and Safety of Single Dose Tranexamic Acid in Reducing Blood Loss During Colorectal Cancer Surgery

Phase 4
Completed
Conditions
Colorectal Surgery
Interventions
Drug: Tranexamic Acid Injection
Drug: placebo injection
Registration Number
NCT03606785
Lead Sponsor
Assiut University
Brief Summary

A total of 46 patients scheduled for explorative laparotomy with the aim of radical debulking surgery for colorectal cancer will be randomized into two equal groups one will receive tranexamic acid and one placebo.

The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision. In the control group, patients will receive a placebo of 100 mL 0.9% normal saline. The primary endpoint is reduction in blood loss, while the secondary endpoint was the number of patients needing transfusion and occurrence of postoperative thrombotic complications (myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
46
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
tranexamic acid groupTranexamic Acid Injection-
placebo groupplacebo injection-
Primary Outcome Measures
NameTimeMethod
reduction in blood loss1 month

Blood loss will be calculated (volume estimated as the blood remaining in sponges and drapes and the volume in suction bottles during surgery).The amount of drained blood will be measured in 1st 24 hours.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

NCI, Cairo university

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath